Descovy® (emtricitabine and tenofovir alafenamide) tablets
Approval Date: May 2024
Indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents
Tybost (cobicistat) tablets
Approval Date: Feb 2024
Indicated for the treatment of HIV-1 infection
Sunlenca® (lenacapavir) tablets
Approval Date: Dec 2022
In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection
Prezista® (darunavir) tablets
Approval Date: Sep 2022
Indicated for the treatment of HIV-1 infection
Apretude (cabotegravir) extended-release injection suspension
Approval Date: Dec 2021
Indicated to reduce the risk of HIV-1 infection
Kaletra® (lopinavir and ritonavir) tablets
Approval Date: Jun 2021
This is the first time a generic has been approved for Kaletra. For the treatment of HIV-1 infection
Intelence® (etravirine) tablets
Approval Date: Jun 2021
This is the first time a generic has been approved for Intelence. For the treatment of HIV-1 infection in treatment-experienced patients
Cabenuva (cabotegravir and rilpivirine extended-release injectable suspension)
Approval Date: Jan 2021
A complete regimen for the treatment of HIV-1 infection to replace current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the first FDA-approved injectable, complete regimen for HIV, administered once a month
Norvir® (ritonavir) capsules
Approval Date: Dec 2020
Indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection
